Inhaled Antibiotics as Adjunct Therapy Should Be Evaluated in Conjunction with Systemic Antibiotic Treatments
Background
Ventilator-associated pneumonia (VAP) is a significant concern in intensive care units, often complicated by multidrug-resistant organisms. The use of adjunctive inhaled antibiotics, such as colistin, has been proposed to enhance treatment efficacy. However, the pharmacokinetics of nebulized colistin raise concerns about systemic absorption and potential nephrotoxicity, necessitating careful evaluation in clinical practice.
Data Highlights
No specific numerical data or trial results are provided in the source material.
Key Findings
Adjunctive inhaled antibiotics may be considered for VAP, but their use must be evaluated alongside systemic antibiotics.
Studies indicate that nebulized colistin can lead to systemic absorption, raising concerns about nephrotoxicity.
In a study by Jang et al., nephrotoxicity was significantly lower in patients receiving nebulized colistin compared to IV colistin (15.7% vs. 60.5%, P < 0.0001).
Pharmacokinetic evidence suggests that nebulized colistin can achieve plasma concentrations comparable to those from intravenous administration.
Approximately 13–17% of nebulized colistimethate sodium is recovered in urine, indicating systemic absorption.
Clinical Implications
Clinicians should be cautious when prescribing nebulized colistin, particularly in conjunction with intravenous colistin, due to the risk of cumulative systemic exposure and nephrotoxicity.
Conclusion
The use of adjunctive inhaled antibiotics in VAP requires careful consideration of their pharmacokinetic properties and potential systemic effects.
